How to Bring a Point-of-Care Diagnostic Test to Market Successfully in 2026

A data-driven approach to adoption, targeting, and scale

Bringing a point-of-care (POC) diagnostic test to market is fundamentally different from launching a pharmaceutical or a medical device. While drug commercialization centers on prescribers and devices rely on capital purchasing and procedural champions, diagnostics succeed—or fail—based on whether they integrate seamlessly into existing clinical behavior.

Most diagnostic companies do not fail because their test lacks clinical validity. They fail because their go-to-market strategy is built on assumptions about how care should work, rather than evidence of how care actually works.

This article outlines how POC diagnostics typically go to market, why many launches stall, and then walks through the most critical go-to-market questions diagnostic teams must answer before scaling. Throughout, we highlight how Alpha Sophia can be used to answer these questions with real-world data instead of intuition.

How point-of-care diagnostic tests usually go to market

Most POC diagnostic companies follow one of three commercialization paths, often without explicitly choosing one.

Some pursue a lab-anchored go-to-market strategy, modeled after large diagnostics incumbents. In this approach, adoption flows through reference labs, pathology departments, or health-system lab leadership. Sales efforts focus on lab directors, procurement committees, and system-level contracts. While this can enable scale, it often distances the test from the clinician’s real decision point—especially when the test is designed to influence care immediately.

Others attempt a provider-direct strategy, selling directly to clinicians in primary care, urgent care, or specialty practices. This is common among newer decentralized diagnostics companies. These teams emphasize speed, convenience, and actionable results, but often underestimate how entrenched lab workflows, ordering habits, and reimbursement expectations are.

The most common—and most difficult—approach is a hybrid strategy, where adoption depends simultaneously on provider trust, lab alignment, reimbursement clarity, and operational approval. Without a deep understanding of who actually drives decisions in each care setting, these launches frequently stall after early pilots.

Why point-of-care diagnostics are not pharma or device go-to-market

Pharmaceutical go-to-market strategies are relatively linear. There is a defined prescriber, established reimbursement pathways, and a familiar sales motion focused on education and detailing.

Medical devices, particularly capital equipment, are sold through long sales cycles driven by procedural champions, value analysis committees, and formal training programs.

Point-of-care diagnostics are different. They compete not only with other tests, but with clinical intuition, empiric treatment, imaging, referrals, and existing lab protocols. A diagnostic test is adopted only if it improves decision-making without adding friction to already constrained workflows. If it does not, it is quietly ignored.

That makes pre-launch market intelligence far more important for diagnostics than for drugs or devices.

The most important go-to-market questions for point-of-care diagnostics

Below are the most critical questions diagnostic companies must answer. These are the questions that determine whether a POC test becomes embedded in care—or stalls after initial interest.

Which providers actually encounter the diagnostic decision moment this test is meant to address?

A common mistake in diagnostic GTM is targeting the specialty most associated with a disease rather than the clinicians who first encounter the condition in practice.

For example, early kidney disease, respiratory infections, metabolic abnormalities, and many inflammatory conditions are often identified in primary care, urgent care, or emergency settings, not by specialists. A diagnostic company that focuses only on nephrologists or pulmonologists may miss the majority of real-world use cases.

Using Alpha Sophia, teams can analyze ICD-10 diagnosis frequency by specialty and provider type, revealing which clinicians are truly positioned to use the test at the point of care. This often reshapes targeting strategy entirely.

Which ICD-10 diagnoses trigger the real-world use of this test?

Point-of-care diagnostics are ordered during specific diagnostic moments, not at the disease-label level used in marketing decks.

For example, a respiratory diagnostic may be marketed around pneumonia, but in practice it is considered during visits coded as J06 (acute upper respiratory infection) or J20 (acute bronchitis). If sales messaging and targeting do not align with these codes, providers will not recognize the test as relevant.

Alpha Sophia allows teams to filter and rank ICD-10 codes most frequently used by target providers, ensuring that GTM strategy reflects how clinicians actually think and document care.

In which site-of-care settings does this test operationally make sense?

Not all care settings are equally receptive to point-of-care diagnostics. Hospital-owned specialty clinics often rely on centralized labs, while urgent care centers, retail clinics, and independent practices are structurally designed for in-office testing.

A rapid infectious disease test, for example, may thrive in urgent care but fail in hospital outpatient departments due to lab politics and procurement processes.

Alpha Sophia’s site-of-care and practice location filters allow teams to segment providers by hospital-based, outpatient clinic, ASC, or independent practice, helping prioritize environments where adoption is operationally realistic.

Which labs are providers already integrated with, and how entrenched are those relationships?

Providers rarely switch labs casually. Long-standing relationships with national reference labs, regional labs, or health-system labs are deeply embedded in ordering workflows and EHR integrations.

For instance, a cardiology practice tightly integrated with a national reference lab may resist adopting an in-office diagnostic unless it clearly fills a gap that existing lab workflows cannot address.

Alpha Sophia maps provider–lab affiliations and organizational relationships, helping diagnostic teams decide whether they need a lab partnership strategy or whether they should focus on lab-independent practices first.

Is this test replacing an existing diagnostic—or replacing no test at all?

Many diagnostic companies assume they are competing with another assay, when in reality they are competing with clinical judgment, empiric treatment, or delayed testing.

For example, some infectious disease diagnostics are competing with the decision to prescribe antibiotics without testing. Others compete with imaging or referral rather than another lab test.

Using Alpha Sophia’s CPT and HCPCS filtering, teams can see what procedures or tests providers currently bill in similar scenarios—or whether no diagnostic is used at all. This distinction has major implications for pricing, messaging, and adoption expectations.

Where does this test sit in the real clinical workflow?

Point-of-care diagnostics succeed when they align naturally with existing workflow sequencing. A test positioned as a first-line rule-out behaves very differently from one positioned after imaging or referral.

If a test adds steps, delays decisions, or creates uncertainty around next actions, it will not be adopted—even if it is clinically sound.

Alpha Sophia supports analysis of diagnosis–procedure relationships, helping teams understand how diagnostics, imaging, referrals, and treatment decisions actually sequence in real practice.

Which providers consistently adopt new diagnostics and clinical tools early?

Not all clinicians adopt innovation at the same pace. Providers involved in clinical trials, publishing, or academic medicine often adopt new diagnostics earlier and influence peers.

These early adopters are critical for pilots, reference accounts, and early validation.

Alpha Sophia identifies these providers using clinical trial participation, publication data, and academic affiliations, allowing diagnostic companies to seed adoption strategically rather than randomly.

Who actually controls purchasing and adoption decisions in each care setting?

In many point-of-care environments, physicians do not make purchasing decisions. Clinic managers, lab directors, health-system administrators, or procurement committees often control adoption.

Misidentifying the economic buyer leads to stalled sales cycles and wasted effort.

Alpha Sophia reveals organizational hierarchies and affiliations, enabling teams to target the true decision-makers for each care setting.

How should adoption be forecast using real provider behavior rather than top-down TAM assumptions?

Many diagnostic forecasts assume uniform adoption across all eligible providers, leading to overestimation and missed expectations.

A more realistic approach models adoption bottom-up, based on:

• Number of relevant providers

• Frequency of relevant diagnoses

• Site-of-care constraints

• Early-adopter penetration

Alpha Sophia supports bottom-up forecasting by grounding projections in real provider counts, diagnostic frequency, and care-setting data.

Final takeaway

Point-of-care diagnostic tests do not succeed because they are innovative. They succeed because they fit into real clinical behavior, real workflows, and real incentives.

The diagnostic companies that win are those that:

• Understand who actually diagnoses conditions

• Align targeting with ICD-10 reality

• Respect lab and workflow dynamics

• Choose launch markets deliberately

• Ground forecasts in real behavior

Alpha Sophia enables diagnostic teams to answer these questions before launch—turning market complexity into clarity and reducing the risk of stalled adoption.

Further reading

👉 Optimizing Sales Targeting for Healthcare Professionals and Organizations

👉 How Can You Optimize HCP Target Lists to Drive Brand Success?